CVRx slumps as heart failure therapy fails post-market trial

CVRx

21/02/2023 15:11

** Shares of CVRx Inc  CVRX.O  slump 27.9% to $12.4
    ** Medical device maker says its chronic heart failure
therapy, Barostim, did not reach statistical significance or
meet main goal in post-market phase of trial 
    ** The trial assessed 323 patients suffering from heart
failure with reduced ejection fraction (HFrEF), with a primary
goal of reduction in worsening heart failure events requiring
treatment in the hospital or emergency department 
    ** Patients with HFrEF have increased pressure on the left
ventricular, the main pumping chamber of the heart, while the
ejection fraction is a measure of whether the left ventricle is
pumping normally 
    ** CVRX stock had risen ~50% in 2022
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))